Norbert Riedel - Aptinyx President CEO, Director
| APTXDelisted Stock | USD 0.07 0.01 16.67% |
CEO
Dr. Norbert G. Riedel is President, Chief Executive Officer, Director of the company. Dr. Riedel has served as a member of our board of directors and our President and Chief Executive Officer since June 2015. Dr. Riedel previously served as Chief Executive Officer and President of Naurex Inc., our predecessor company, from January 2014 to July 2015. From 2001 to January 2013, he served as Corporationrationrate Vice President and Chief Scientific Officer of Baxter International Inc., a diversified healthcare company, where from 1998 to 2001, he also served as President and General Manager of the recombinant therapeutic proteins business unit and Vice President of Research and Development of the bioscience business unit. From 1996 to 1998, Dr. Riedel served as head of worldwide biotechnology and worldwide core research functions at HoechstMarion Roussel, now Sanofi, a global pharmaceutical company. Dr. Riedel served on the board of directors of Ariad Pharmaceuticals, Inc., an oncology company, from May 2011 until the company was acquired in February 2017. Dr. Riedel also serves on the board of directors of Jazz Pharmaceuticals plc and the Illinois Biotechnology Industry Organization and is also a member of the Austrian Academy of Sciences. Dr. Riedel is an Adjunct Professor at Boston University School of Medicine and an Adjunct Professor of Medicine at Northwestern University Feinberg School of Medicine. Dr. Riedel previously served as an associate professor of medicine at Boston University School of Medicine and a visiting associate professor at the Massachusetts Institute of Technology. Dr. Riedel holds a Diploma in biochemistry and a Ph.D. in biochemistry from the University of Frankfurt. Dr. Riedel brings significant scientific, drug discovery and development, and commercial expertise to our board of directors with over 20 years of experience in the biotechnology and pharmaceutical industries. since 2015.
| Age | 65 |
| Tenure | 9 years |
| Professional Marks | Ph.D |
| Phone | 847 871 0377 |
| Web | https://www.aptinyx.com |
Aptinyx Management Efficiency
The company has return on total asset (ROA) of (0.5135) % which means that it has lost $0.5135 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (1.3806) %, meaning that it created substantial loss on money invested by shareholders. Aptinyx's management efficiency ratios could be used to measure how well Aptinyx manages its routine affairs as well as how well it operates its assets and liabilities.Aptinyx currently holds 22.11 M in liabilities with Debt to Equity (D/E) ratio of 0.39, which is about average as compared to similar companies. Aptinyx has a current ratio of 15.9, suggesting that it is liquid enough and is able to pay its financial obligations when due. Note, when we think about Aptinyx's use of debt, we should always consider it together with its cash and equity.
Similar Executives
| Found 7 records | CEO Age | ||
| Thomas MBA | Transcode Therapeutics | 72 | |
| Junyuan Wang | Nuvation Bio | 51 | |
| Thomas Jensen | Allarity Therapeutics | 46 | |
| HyungHeon Kim | Neurobo Pharmaceuticals | 49 | |
| Jason Okazaki | Assembly Biosciences | 48 | |
| Cary MBA | Adial Pharmaceuticals | 63 | |
| David Hung | Nuvation Bio | 63 | |
Management Performance
| Return On Equity | -1.38 | |||
| Return On Asset | -0.51 |
Aptinyx Leadership Team
Elected by the shareholders, the Aptinyx's board of directors comprises two types of representatives: Aptinyx inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Aptinyx. The board's role is to monitor Aptinyx's management team and ensure that shareholders' interests are well served. Aptinyx's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Aptinyx's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Kathryn King, VP Operations | ||
| Norbert Riedel, President CEO, Director | ||
| Patrick Flavin, Sr Relations | ||
| Molly Dir, VP HR | ||
| Ashish Khanna, Chief Business Officer | ||
| Harald MD, VP Affairs | ||
| Tim Noffke, VP Staff | ||
| MD BCh, Pres CEO |
Aptinyx Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Aptinyx a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -1.38 | |||
| Return On Asset | -0.51 | |||
| Current Valuation | (25.91 M) | |||
| Shares Outstanding | 67.72 M | |||
| Shares Owned By Insiders | 13.12 % | |||
| Shares Owned By Institutions | 42.96 % | |||
| Number Of Shares Shorted | 2.23 M | |||
| Price To Earning | (5.61) X | |||
| Price To Book | 0.33 X | |||
| Price To Sales | 45.33 X |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in estimate. You can also try the Commodity Directory module to find actively traded commodities issued by global exchanges.
Other Consideration for investing in Aptinyx Stock
If you are still planning to invest in Aptinyx check if it may still be traded through OTC markets such as Pink Sheets or OTC Bulletin Board. You may also purchase it directly from the company, but this is not always possible and may require contacting the company directly. Please note that delisted stocks are often considered to be more risky investments, as they are no longer subject to the same regulatory and reporting requirements as listed stocks. Therefore, it is essential to carefully research the Aptinyx's history and understand the potential risks before investing.
| Balance Of Power Check stock momentum by analyzing Balance Of Power indicator and other technical ratios | |
| Portfolio Comparator Compare the composition, asset allocations and performance of any two portfolios in your account | |
| Competition Analyzer Analyze and compare many basic indicators for a group of related or unrelated entities | |
| Portfolio Manager State of the art Portfolio Manager to monitor and improve performance of your invested capital | |
| Latest Portfolios Quick portfolio dashboard that showcases your latest portfolios | |
| Premium Stories Follow Macroaxis premium stories from verified contributors across different equity types, categories and coverage scope | |
| Earnings Calls Check upcoming earnings announcements updated hourly across public exchanges | |
| Stock Screener Find equities using a custom stock filter or screen asymmetry in trading patterns, price, volume, or investment outlook. | |
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA |